Cardima to Host Scientific Symposium at the CardioRhythm 2007 Conference in Hong Kong on Sunday, February 4th, 2007
FREMONT, CA--(MARKET WIRE)--Jan 31, 2007 -- Cardima, Inc. (OTC BB:CADM.OB - News), developer of the REVELATION® Tx, REVELATION® T-Flex and REVELATION® Helix ablation microcatheters and INTELLITEMP® Energy Management Device, will host a luncheon symposium at the CardioRhythm 2007 Conference to be held at the Hong Kong Convention and Exhibition Center from February 2nd-4th, 2007. Cardima's symposium will showcase the most recent developments in atrial fibrillation (AF) treatment using the REVELATION® family of microcatheters. Approximately 1,500 physicians, medical professionals and industry representatives from the Asian-Pacific region are expected to attend the CardioRhythm conference this year.
Cardima's luncheon symposium, entitled "New System and Techniques for Catheter-Based Treatment of Atrial Fibrillation," will be held on Sunday, February 4th, 2007 at 12:00 p.m. The symposium panel will be chaired by Sung Chun, M.D., Director of Cardiac Electrophysiology, Palo Alto Medical Foundation, California. The other panelist is Jaswinder Gill, MBBChir, MD, FRCP, Director of Pacing and Electrophysiology at Guy's and St. Thomas' Hospitals, London.
We are proud to present the INTELLITEMP®-controlled ablation experiences with the REVELATION® T-Flex and REVELATION® Helix catheters at the CardioRhythm conference," stated Gabriel Vegh, Chief Executive Officer of Cardima.
According to Dr. Eric Chan, Senior Vice President of Product Development of Cardima, "Dr. Chun will discuss the effectiveness of our linear electrode technology as incorporated into our REVELATION® series of catheters and show atrial lesion histology from animal studies performed at Stanford University Medical Center. In addition, Dr. Gill will present his most recent clinical experiences with the REVELATION® T-Flex as an efficacious and faster alternative to other existing ablation procedures for the treatment of atrial fibrillation."
About Cardima
Cardima, Inc. has developed the PATHFINDER® and REVELATION® Series of diagnostic catheters, the INTELLITEMP® Energy Management Device, and the Surgical Ablation System (SAS). All of these devices are CE marked and received U.S. FDA 510(k) clearance. The REVELATION® Series of ablation catheters with the INTELLITEMP® EP Energy Management Device was developed and marketed for the treatment of atrial fibrillation (AF) after receiving CE mark approval in Europe; it is not currently available in the U.S.
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements. Potential risks and uncertainties include: the uncertainties associated with the prospects for FDA approval of any new devices; the prospect for any future clinical trials or regulatory activities; the risk that the Company will not be able to raise additional capital in the immediate term as needed to continue operations and the risk that we will be unable to secure a strategic transaction involving the Surgical Ablation System. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, the Company's Quarterly Report on Form 10-QSB for the third quarter ended September 30, 2007, and in the Company's subsequent SEC filings. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.